AptarGroup has acquired two pharmaceutical services companies, Nanopharm and Gateway Analytical, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and de-risk their complex product developments.
 
Both acquisitions bring complementary, value-added and differentiated analytical, testing and development services for all stages of drug development and commercialization. The expanded services platform will enable Aptar Pharma to collaborate earlier with customers to support their complex drug formulations and delivery requirements as they face increasingly competitive and regulated markets.
 
Nanopharm, located in Newport, UK, is a provider of orally inhaled and nasal drug product design and development services. Gateway Analytical, located in Gibsonia, PA, provides particulate detection and predictive analytical services to customers developing injectable medicines.
 
“We are delighted to welcome the talented teams of Nanopharm and Gateway and their customers to Aptar Pharma,” said Gael Touya, president, Aptar Pharma. “Their expertise and capabilities will deepen our current range of services offered to customers who are developing and testing inhaled and injected medicines. This enables us to participate in a broader spectrum of the pre-clinical, clinical trial and market launch phases of drug development.”
 
Stephan Tanda, president and chief executive officer, said, “These strategic investments further strengthen our best in class pharma business and increase our ability to add to our long-term growth pipeline by adding depth to our service offerings. The expertise of two established leaders, Nanopharm, a leader in inhalation and nasal drug development services, and Gateway, a leader in particulate detection and analysis for the injectables market, are complementary to our existing laboratory and analytical services and will bring additional value to our customers as they navigate the challenging regulatory landscape and seek to bring their products to market faster.”